N-异丙基吡啶-2-甲胺 | 58669-30-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: N-异丙基吡啶-2-甲胺
• 英文名称: 2-(1-(1-methylethylamino)methyl)pyridine
• 英文别名: N-(pyridin-2-ylmethyl)propan-2-amine；N-isopropyl-N-(2-pyridylmethyl)amine；2-(N-isopropylaminomethyl)pyridine；N-isopropyl-N-(2-methylpyridine)；N-isopropyl-N-2-methylpyridine；N-isopropyl-2-picolylamine；N-Isopropylpyridine-2-methylamine
• CAS: 58669-30-0
• 化学式: C₉H₁₄N₂
• mdl: MFCD08757701
• 分子量: 150.224
• InChiKey: YDCNZMOBAPTYRB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  11
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.444
• 拓扑面积：
  24.9
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2933399090

反应信息

• 作为反应物：
  描述：

  N-异丙基吡啶-2-甲胺 在 platinum(IV) oxide 氢气 作用下， 以 水 、 溶剂黄146 为溶剂， 反应 0.75h， 生成 2-isopropylperhydroimidazolo<3,4-a>pyridine
  参考文献：
  名称：

  具有桥头氮 52 的化合物——2-烷基全氢咪唑并[3,4-a]吡啶的核磁共振谱和立体化学

  摘要：

  与全氢恶唑并[3,4-a]吡啶和全氢噻唑并[3,4-a]吡啶相反，它们在室温下在CDCl3溶液中采用平衡，其中含有约70%的与O-或S-平衡的互变构象异构体在顺式融合的构象异构体中，发现 2-烷基全氢咪唑并[3,4-a]吡啶采用含有>98% 的反式融合构象异构体的平衡。2-甲基全氢咪唑并[3,4-a]吡啶的NMR参数与1,2-二甲基全氢咪唑并[3,4-a]吡啶的两种异构体的NMR参数的比较表明前一种化合物在两种反式融合构象异构体之间达到平衡，大约 83% 的构象包含氮孤对电子的反式排列。这些观察结果是根据广义异头效应来解释的。

  DOI：

  10.1002/mrc.1260250808
• 作为产物：
  描述：

  N-(pyridin-2-ylmethyl)propan-2-imine 在 sodium tetrahydroborate 作用下， 以 甲醇 为溶剂， 以1.21 g的产率得到N-异丙基吡啶-2-甲胺
  参考文献：
  名称：

  Oxo Transfer from Nitrogen Dioxide to Nitrito Group in a Copper(II) Complex

  摘要：

  Reaction of Cu(II) complex [Cu-II(LH)(O2CCH3)(2)] (1) [LH = 4,6-ditert-butyl-2-((2-picolyl(isopropyl)atnitio)niethyl)-phenol] with equivalent amount of NO2 leads to the reduction of Cu(II) to Cu(I) with concomitant nitration at the phenol ring of the ligand. This resulted in the in situ formation of intermediate Cu(I) complex of the nitrated ligand (L'H). Additional equivalent of NO2 coordinates to the Cu(I) complex to form corresponding O-nitrito Cu(II) complex [Cu-II(L'(eta(1)-ONO)] (2). Subsequent addition Of NO2 led to the corresponding O-nitrato,complex, [Cu-II(L')(eta(1)-ONO2)] (3) with concomitant formation of NO. Complexes 2 and 3 were isolated and structurally characterized. The formation of NO in the reaction was established by spin-trapping experiment. Isotopic labeling experiment revealed that the oxo transfer takes place from NO2 to the coordinated eta(1)-ONO group.

  DOI：

  10.1021/acs.inorgchem.5b00242

文献信息

• BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE
  申请人：Arvinas Operations, Inc.

  公开号：US20190300521A1

  公开（公告）日：2019-10-03

  The present disclosure relates to bifunctional compounds, which find utility as modulators of SMARCA2 or BRM (target protein). In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a ligand that binds to the Von Hippel-Lindau E3 ubiquitin ligase, and on the other end a moiety which binds the target protein, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/inhibition of target protein. Diseases or disorders that result from aggregation or accumulation of the target protein are treated or prevented with compounds and compositions of the present disclosure.

  本公开涉及双功能化合物，其作为SMARCA2或BRM（靶蛋白）的调节剂具有实用性。具体而言，本公开涉及包含一端结合Von Hippel-Lindau E3泛素连接酶的配体，另一端结合靶蛋白的双功能化合物，使得靶蛋白与泛素连接酶靠近以实现靶蛋白的降解（和抑制）。本公开展示了与靶蛋白降解/抑制相关的广泛药理活性。本公开的化合物和组合物用于治疗或预防由靶蛋白聚集或积累导致的疾病或紊乱。
• TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE
  申请人：Arvinas, Inc.

  公开号：US20180125821A1

  公开（公告）日：2018-05-10

  The present disclosure relates to bifunctional compounds, which find utility as modulators of tau protein. In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a VHL or cereblon ligand which binds to the E3 ubiquitin ligase and on the other end a moiety which binds tau protein, such that tau protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of tau. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/inhibition of tau protein. Diseases or disorders that result from aggregation or accumulation of tau protein are treated or prevented with compounds and compositions of the present disclosure.

  本公开涉及双功能化合物，其作为tau蛋白的调节剂具有实用性。具体而言，本公开涉及含有一端结合到E3泛素连接酶的VHL或cereblon配体，另一端结合到tau蛋白的双功能化合物，使得tau蛋白与泛素连接酶靠近，以实现tau蛋白的降解（和抑制）。本公开展示了与tau蛋白降解/抑制相关的广泛药理活性。本公开的化合物和组合物用于治疗或预防由tau蛋白聚集或积累导致的疾病或紊乱。
• HEPATITIS C VIRUS INHIBITORS AND USES THEREOF IN PREPARATION OF DRUGS
  申请人：CHANGZHOU YINSHENG PHARMACEUTICAL CO., LTD.

  公开号：US20170253614A1

  公开（公告）日：2017-09-07

  A series of hepatitis C virus (HCV) inhibitors and compositions and applications thereof in the preparation of drugs for treating chronic HCV infection. Especially, a series of compounds that are used as NS5A inhibitors, and compositions and uses thereof in the preparations of drugs.

  一系列丙型肝炎病毒（HCV）抑制剂及其组合物，以及在制备用于治疗慢性HCV感染的药物时的应用。特别是一系列用作NS5A抑制剂的化合物，以及在药物制剂中的组合物和用途。
• BENZIMIDAZOLE AND IMADAZOPYRIDINE CARBOXIMIDAMIDE COMPOUNDS
  申请人：Gilead Sciences, Inc.

  公开号：US20160333009A1

  公开（公告）日：2016-11-17

  The present disclosure provides indoleamine 2,3-dioxygenase 1 (IDOL) inhibitors of Formula I: or pharmaceutically acceptable salts thereof, in which X, L, n, m, R 1 , R 2a , R 2b , R n , R m , and R t are as defined herein, as well as pharmaceutical compositions that include a compound of Formula I, or pharmaceutically acceptable salts thereof, and methods of using the same to treat conditions mediated by IDO1.

  本公开提供了式I的吲哌酮2,3-二氧化酶1（IDOL）抑制剂： 或其药学上可接受的盐，其中X、L、n、m、R 1 、R 2a 、R 2b 、R n 、R m 和R t 如本文所定义，以及包括式I化合物的药物组合物，或其药学上可接受的盐，并使用这些方法来治疗由IDO1介导的疾病。
• [EN] COMBINATION PHARMACEUTICAL AGENTS AS RSV INHIBITORS<br/>[FR] AGENTS PHARMACEUTIQUES EN COMBINAISON EN TANT QU'INHIBITEURS DE RSV
  申请人：ENANTA PHARM INC

  公开号：WO2019067864A1

  公开（公告）日：2019-04-04

  The present invention relates to pharmaceutical agents administered to a subject either in combination or in series for the treatment of a Respiratory Syncytial Virus (RSV) infection, wherein treatment comprises administering a compound effective to inhibit the function of the RSV and an additional compound or combinations of compounds having anti-RSV activity.

  本发明涉及用于治疗呼吸道合胞病毒（RSV）感染的药物剂，该药物剂可以单独或连续给予受试者，治疗包括给予一种有效抑制RSV功能的化合物以及具有抗RSV活性的另一种化合物或化合物组合。